Rowland M - Search Results

1

Physiologically-based pharmacokinetics in drug development and regulatory science.

Rowland M, Peck C, Tucker G. Rowland M, et al. Annu Rev Pharmacol Toxicol. 2011;51:45-73. doi: 10.1146/annurev-pharmtox-010510-100540. Annu Rev Pharmacol Toxicol. 2011. PMID: 20854171 Review.

2

Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002).

Rowland M, Balant L, Peck C. Rowland M, et al. AAPS PharmSci. 2004 Feb 9;6(1):E6. doi: 10.1208/ps060106. AAPS PharmSci. 2004. PMID: 15198507 Free PMC article.

3

Impact of the pharmaceutical sciences on health care: a reflection over the past 50 years.

Rowland M, Noe CR, Smith DA, Tucker GT, Crommelin DJ, Peck CC, Rocci ML Jr, Besançon L, Shah VP. Rowland M, et al. J Pharm Sci. 2012 Nov;101(11):4075-99. doi: 10.1002/jps.23295. Epub 2012 Aug 21. J Pharm Sci. 2012. PMID: 22911654

4

Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.

Lesko LJ, Rowland M, Peck CC, Blaschke TF. Lesko LJ, et al. Among authors: rowland m. J Clin Pharmacol. 2000 Aug;40(8):803-14. doi: 10.1177/00912700022009530. J Clin Pharmacol. 2000. PMID: 10934664

5

Symbols in pharmacokinetics.

Rowland M, Tucker G. Rowland M, et al. J Pharmacokinet Biopharm. 1980 Oct;8(5):497-507. doi: 10.1007/BF01059548. J Pharmacokinet Biopharm. 1980. PMID: 7252793

6

Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.

Lesko LJ, Rowland M, Peck CC, Blaschke TF. Lesko LJ, et al. Among authors: rowland m. Pharm Res. 2000 Nov;17(11):1335-44. doi: 10.1023/a:1007574217260. Pharm Res. 2000. PMID: 11205725 Review. No abstract available.

7

Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.

Lesko LJ, Rowland M, Peck CC, Blaschke TF, Breimer D, de Jong HJ, Grahnen A, Kuhlmann JJ, Stewart B. Lesko LJ, et al. Among authors: rowland m. Eur J Pharm Sci. 2000;10(4):iv-xiv. doi: 10.1016/s0928-0987(00)00092-0. Eur J Pharm Sci. 2000. PMID: 11023342 No abstract available.

8

Use of dried blood spots in drug development: pharmacokinetic considerations.

Rowland M, Emmons GT. Rowland M, et al. AAPS J. 2010 Sep;12(3):290-3. doi: 10.1208/s12248-010-9188-y. Epub 2010 Apr 10. AAPS J. 2010. PMID: 20383669 Free PMC article.

9

Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases.

Rodgers T, Leahy D, Rowland M. Rodgers T, et al. Among authors: rowland m. J Pharm Sci. 2005 Jun;94(6):1259-76. doi: 10.1002/jps.20322. J Pharm Sci. 2005. PMID: 15858854

10

Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS.

Gueorguieva I, Aarons L, Rowland M. Gueorguieva I, et al. Among authors: rowland m. J Pharmacokinet Pharmacodyn. 2006 Oct;33(5):571-94. doi: 10.1007/s10928-006-9023-3. Epub 2006 Jun 29. J Pharmacokinet Pharmacodyn. 2006. PMID: 16810558

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,030 results

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,030 results